Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The retroviral restriction factor TRIM5alpha.

Sarah Sebastian1, Jeremy Luban

  • 1Institute for Research in Biomedicine, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland.

Current Infectious Disease Reports
|February 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolates.

bioRxiv : the preprint server for biology·2026
Same author

Transition from infectivity and immune escape to pure escape as an evolutionary strategy during the COVID-19 pandemic.

bioRxiv : the preprint server for biology·2026
Same author

A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-Risk Human Papillomavirus Vaccine in Women with Low-grade Cervical Lesions.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Navigating vaginal delivery in a patient with severe uterine prolapse: A case report.

Case reports in women's health·2025
Same author

Computationally designed proteins mimic antibody immune evasion in viral evolution.

Immunity·2025
Same author

Molecular basis for the increased fusion activity of the Ebola virus glycoprotein epidemic variant A82V: Insights from simulations and experiments.

Cell reports·2025
Same journal

Chagas Disease: An Opportunistic Infection in AIDS.

Current infectious disease reports·2026
Same journal

Area-based Deprivation Indices and Healthcare-Associated Infections: A Narrative Review of Evidence.

Current infectious disease reports·2025
Same journal

Next Steps: Studying Diabetic Foot Infections with Next-Generation Molecular Assays.

Current infectious disease reports·2024
Same journal

To Tweet or Not to Tweet-a Review of the Viral Power of Twitter for Infectious Diseases.

Current infectious disease reports·2024
Same journal

Web alert.

Current infectious disease reports·2024
Same journal

Bacterial Vaginosis in Postmenopausal Women.

Current infectious disease reports·2023
See all related articles

Host cells possess retroviral restriction factors, like TRIM5, that inhibit viral replication. This review highlights recent findings on TRIM5, a key factor potently restricting HIV-1 and other retroviruses.

Area of Science:

  • Virology
  • Immunology
  • Molecular Biology

Background:

  • Retroviruses are intracellular parasites relying on host factors for replication.
  • Host cells have evolved antiviral proteins, termed restriction factors, to counteract retroviruses.
  • Several restriction factors, including TRIM5, APOBEC3F/G, and ZAP, have been identified.

Purpose of the Study:

  • To review recent advancements in understanding TRIM5.
  • To highlight TRIM5's role as a potent inhibitor of retroviral replication, including HIV-1.

Main Methods:

  • Literature review of publications from the past two years.
  • Focus on studies investigating TRIM5's antiviral mechanisms and host interactions.

Main Results:

Related Experiment Videos

  • TRIM5 is a significant retroviral restriction factor.
  • TRIM5 potently inhibits the replication of HIV-1 and various other retroviruses.
  • Recent research has significantly expanded the knowledge of TRIM5's function.

Conclusions:

  • TRIM5 represents a critical component of the innate immune system against retroviral infections.
  • Further research into TRIM5 may reveal new therapeutic strategies against retroviruses like HIV-1.